BoneBio: Breast cancer and bone biomarkers: Poster to abstract #24 BoneBio: The variable sensitivity of breast cancer patients to zoledronic acid

Bidragets oversatte titel: BoneBio: Brystkræft og knogle biomarkører

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskning

Abstrakt

#24 BoneBio: The variable sensitivity of breast cancer patients to zoledronic acid Presenting author: Anaïs Marie Julie Møller Presenting author's affiliation: Clinical Cell Biology, Department of Pathology, Odense University Hospital; Department of Clinical Research, University of Southern Denmark Authors: Møller, A. M. J. (1), Bechmann, T. (2), Madsen, J. M. (3), Jakobsen E. H. (2), Søe K. (4) Affiliations: 1: Clinical Cell Biology, Department of Pathology, Odense University Hospital; Department of Clinical Research,University of Southern Denmark 2: Department of Oncology, Vejle Hospital; Department of Oncology, Hospital of South West Jutland 3: Department of Clinical Immunology and Biochemistry, Vejle Hospital 4: Clinical Cell Biology, Department of Pathology, Odense University Hospital; Department of Clinical Research, University of Southern Denmark; OPEN – Open patient data Explorative Network Abstract: Introduction Breast cancer (BC) is the most prevalent cancer among women in Denmark. BC cells frequently metastasize to bone tissue, where they initiate a “vicious cycle” involving the bone resorbing osteoclasts. This results in local bone loss, increased fracture risk, resistance of cancer cells, a reduced quality of life, and survival. Questions Can bone biomarkers (CTX: degradation, PINP: formation) be used for diagnosis and monitoring? Can it detect those patients that are least sensitive to zoledronic acid? Materials and methods 50 BC patients with newly diagnosed bone metastases (80 years or younger). Primary variables: absolute and delta‐values of CTX and PINP, progression of bone disease, and death. Preliminary results Start of recruitment: May 2016 ‐ status: 49/50 pts. After 3 months of treatment with zoledronic acid the median CTX levels are decreased by 69% from baseline (p<0.0001) while median PINP levels are decreased by 62% (p=0.0008). But the percent change from baseline after 3 months of treatment varies from +170% to ‐90% for CTX and from +300% to ‐92% for PINP, indicating large variations in sensitivity to zoledronic acid among patients. In addition, our results indicate that the 9 patients that have died so far were all amongst the less sensitive. Finally, patients with clinical signs of progression in bone disease show elevated marker levels several months in advance. Conclusions Bone biomarkers CTX and PINP seem promising as a complementary tool for diagnosis and monitoring of BC patients with bone metastases. The trial is still ongoing and the last patient is expected to leave the trial in 1 to 3 years. We hope to determine thresholds for PINP and CTX that can be used to detect relapse in bone disease earlier than today. A future routine use of these markers may lead to new individualized treatment strategies improving quality of life and possibly survival.
Bidragets oversatte titelBoneBio: Brystkræft og knogle biomarkører
OriginalsprogEngelsk
Publikationsdato29. aug. 2019
Antal sider1
StatusUdgivet - 29. aug. 2019
BegivenhedDanish Cancer Research Days: Danske Kræftforskningsdage - Odense , Danmark
Varighed: 29. aug. 201930. aug. 2019
Konferencens nummer: 2

Konference

KonferenceDanish Cancer Research Days
Nummer2
LandDanmark
ByOdense
Periode29/08/201930/08/2019

Fingeraftryk Dyk ned i forskningsemnerne om 'BoneBio: Brystkræft og knogle biomarkører: Poster to abstract #24 BoneBio: The variable sensitivity of breast cancer patients to zoledronic acid'. Sammen danner de et unikt fingeraftryk.

  • Citationsformater